Search

Researchers have submitted a patent application for a blood cell analyzer that aims to evaluate infection status, including sepsis, in patients. The device uses novel blood cell morphological parameters to provide early prediction, diagnosis, and monitoring of infections, without requiring additional testing costs. The patent application focuses on improving the accuracy and timeliness of diagnosing infectious diseases, such as sepsis, using existing blood cell analyzers. [Extracted from the article]

A patent application titled "Blood Cell Analyzer, Method And Use Of Infection Marker Parameter" by Shenzhen Mindray Bio-Medical Electronics Co. Ltd aims to provide a solution for diagnosing infectious diseases, particularly sepsis, by predicting the likelihood of progression to sepsis in patients. The invention involves a blood cell analyzer that calculates leukocyte parameters from optical information in a blood sample to predict sepsis development within a certain period. By utilizing infection marker parameters, clinicians can make timely and effective treatment plans for patients at risk of sepsis. [Extracted from the article]

A patent has been issued for a treatment method for acute medical conditions by Galvani Bioelectronics Limited. The method involves stimulating the neural activity of nerves supplying the spleen to improve physiological parameters indicative of treating acute conditions like trauma, hemorrhaging, and septic shock. This innovative approach aims to stabilize blood pressure, restore heart rate, and address other critical physiological changes associated with life-threatening conditions. The patent highlights the potential of neuromodulation in providing effective treatment for acute medical conditions. [Extracted from the article]

VolitionRx Limited conducted a symposium at ESICM Lives 2024, presenting findings that suggest the Nu.Q(R) NETs test could help predict sepsis patients at risk of deteriorating. Three large studies in France, Germany, and the Netherlands involving over 3,000 sepsis patients utilized Volition's test to measure levels of circulating H3.1 nucleosomes, a marker for Neutrophil Extracellular Traps (NETs). This research may have implications for improving sepsis management and patient outcomes. [Extracted from the article]

Ad Astra Diagnostics (AAD) has been awarded a federal contract to develop an improved diagnostic system for faster complete blood count (CBC) test results and early detection of severe infections, including sepsis. The QScout CBC system, designed for community settings like physician offices and ambulances, aims to provide comprehensive CBC results and aid in the early identification of severe infections. This project, funded by BARDA, seeks to enhance diagnostic capabilities and improve patient outcomes by enabling quicker and easier CBC testing. [Extracted from the article]

Immunexpress, Pty Ltd., a molecular diagnostics company, published a study in the Journal of Clinical Medicine demonstrating the clinical utility of SeptiCyte RAPID in identifying sepsis in diverse patient populations. The test effectively discriminated between sepsis and SIRS across different races, medical conditions, and therapeutic regimens, allowing for individualized treatments. SeptiCyte RAPID performed well in identifying septic shock in patients from various racial groups and underlying disease states, showing consistent performance across different patient subgroups. This research highlights the importance of phenotypic stratification in categorizing sepsis patients based on clinical severity for appropriate therapeutic interventions. [Extracted from the article]

A recent study conducted by researchers at Metabolon Inc. highlights the role of metabolic dysregulation in septic shock, a condition associated with high mortality rates. The study found that septic shock patients experience a shift from hyper-inflammation to hypo-inflammation, making them susceptible to secondary infections. The researchers analyzed plasma metabolites and immune response in septic shock patients and healthy controls, and found that the accumulation of metabolites from various metabolic pathways influences the immune response profile of circulating cells. This research provides valuable insights into the immunometabolic chaos in septic shock. [Extracted from the article]

Accelerate Diagnostics, Inc. has received FDA clearance for its Accelerate Arc system and BC kit, which automates positive blood culture sample preparation for microbial identification. The system eliminates the need for overnight culture methods, reducing wait times for results and aiding in the fight against sepsis. The Arc system can also replace laborious sample preparation methods and is FDA-cleared for clinical laboratory use. The company aims to provide faster and more actionable results to clinicians, ultimately improving patient care and outcomes. [Extracted from the article]

A recent study conducted by bioMerieux Inc. explores the impact of rapid antimicrobial susceptibility testing (AST) on patients with bloodstream infections (BSIs). The study highlights that recent technological advancements have allowed for faster determination of susceptibility, resulting in improved antibiotic therapy selection and patient outcomes. While observational studies have shown the clinical impact of rapid AST, randomized controlled trials have not yet validated these findings. The article also discusses various metrics used to measure the impact of rapid AST and how implementation and workflow processes can affect these metrics. [Extracted from the article]

Galvani Bioelectronics Limited has been issued a patent for the treatment of acute medical conditions. The patent describes a method for stimulating the neural activity of a nerve supplying the spleen, which has been shown to increase survival in animals with endotoxemic shock. The invention provides a system for applying an electrical signal to the nerve, which improves various physiological parameters indicative of treatment for acute medical conditions. This method could be particularly useful in acute clinical settings for conditions such as trauma, hemorrhaging, and septic shock. [Extracted from the article]

The article provides information on a patent application filed by the inventors Alejandro Covalin, Christopher Czura, and Navid Khodaparast on February 21, 2024 and was made available online on August 29, 2024. Spark Biomedical Inc. is the assignee for the patent application. Also mentioned are the risk associated with improper blood management, how the possibility of bleeding in a prophylactic manner before any bleeding occurs can be mitigated, and the claims supplied by the inventors.

The article reports on the issuance of a patent for nitric oxide and chlorhexidine releasing catheter for anti-platelet and antimicrobial dual functionality to Becton Dickinson and Co. The inventors James Freasier, Brendan Laine, and Gidon Ofek filed the patent on November 9, 2020 and published it online on August 27, 2024. The disclosure relates to a catheter impregnated and coated with nitric oxide (NO) releasing compound(s) and chlorhexidine. The claims supplied by the inventors are noted.

The article focuses on a newly issued patent for a method and kit for isolating and analyzing the morphology of cells. Topics include the method's ability to dissociate cell colonies into single cells, its advantages over traditional cell immobilization techniques, and its potential application in improving antibiotic susceptibility tests.

A recent study conducted by bioMerieux in Salt Lake City, Utah, explored the use of rapid antimicrobial susceptibility testing (AST) methods for patients with bloodstream infections. The study found that these methods demonstrated excellent performance for gram-negative organisms directly from blood cultures. The results showed high categorical agreements and low error rates, suggesting that locally validated direct-from-blood AST protocols offer reliable and fast results, particularly in resource-limited settings. However, further research is needed to assess the performance of rapid AST protocols for gram-positive organisms. [Extracted from the article]

A patent application has been submitted by Kurin Inc. for a "Blood Sample Optimization Device" that aims to reduce blood culture contamination, lysing of cells, and vein collapse during blood sample collection. The device includes an inlet port, an outlet port, a sequestration chamber with an air permeable blood barrier, and a sampling channel. By using the patient's own blood pressure, the device passively withdraws blood, reducing the risk of vein collapse. The device can be used with various blood collection systems and can improve the accuracy and reliability of blood culture results. [Extracted from the article]

A recent publication in the Acta Materia Medica journal explores the potential pharmacological action of Cordyceps sinensis (CS) in sepsis-associated acute kidney injury (S-AKI). CS treatment was found to effectively improve renal function and reduce inflammation in mice with S-AKI induced by lipopolysaccharide (LPS). Multi-omic analyses suggest that CS promotes mitochondrial energy metabolism and macrophage polarization, which may contribute to its protective effects against S-AKI. These findings provide new insights into the clinical use of CS for the prevention and treatment of S-AKI. [Extracted from the article]

The USPTO has published a patent application titled "Medium Molecular Weight Heparin For Use In The Treatment Of Endotheliopathy," which explores the role of endothelial cells in regulating blood flow and maintaining homeostasis. The application emphasizes the significance of endothelial dysfunction, or endotheliopathy, in various diseases, including COVID-19. It suggests the potential use of medium molecular weight heparin as a treatment for endotheliopathy, specifically targeting the impaired function of endothelial cells. The application provides background information on heparin and its interaction with von Willebrand Factor (VWF) in the context of endothelial dysfunction. It also discusses the potential benefits of this treatment for patients with diseases such as COVID-19, cancer, cardiovascular disease, and bacterial infections. The patent application includes detailed claims and additional information for further exploration. [Extracted from the article]

Asep Medical Holdings Inc. has announced that its sepsis diagnostic test will be featured in a national documentary series called Empowered, hosted by Meg Ryan and airing on Public Television. The documentary aims to educate viewers about the seriousness of sepsis and highlight Asep's innovative technology for rapid sepsis identification. The test, called SepsetER, has shown promising results in assessing the risk of sepsis onset in ICU and emergency department patients. Asep Inc. hopes that the documentary will raise awareness about sepsis and the importance of early diagnosis and treatment. [Extracted from the article]

A patent has been issued for a device and method that allows for the non-invasive detection and destruction of bacterial cells in blood vessels. This technique involves injecting contrast agents into the vessel, which are then targeted and destroyed using laser energy. The method has the potential to address antibiotic resistance and provide a new approach to treating bacteremia. The patent also describes various applications for the device, including diagnosing and treating conditions such as infection, viruses, clots, and immunodeficiency disorders. The device can be used in a wide range of organisms and can be customized based on specific needs. [Extracted from the article]

Armata Pharmaceuticals has received an additional $5.25 million in funding from the U.S. Department of Defense to support its ongoing clinical trial of AP-SA02, a potential treatment for complicated Staphylococcus aureus bacteremia. The grant was awarded through the Medical Technology Enterprise Consortium and managed by the Naval Medical Research Command. The diSArm study is a Phase 1b/2a trial evaluating the safety, tolerability, and efficacy of AP-SA02 as an adjunct to antibiotic therapy for adults with bacteremia due to Staphylococcus aureus. The study is currently 68% enrolled and is expected to enroll approximately 50 subjects. [Extracted from the article]

Researchers have submitted a patent application for the use of nitazoxanide (NTZ) in the treatment of sepsis. Sepsis is a dysregulated immune response to infection that can lead to organ dysfunction and is a common cause of death in intensive care units. The inventors have found that NTZ improves survival in a preclinical model of sepsis and directly protects hepatocytes from cytokine-induced cell death. The compound can be used to protect vital organs, inhibit cytokine-induced apoptosis, and slow or stop the progression of sepsis. It can be used as a single agent or in combination with an antimicrobial agent. [Extracted from the article]

A patent has been issued to Tulavi Therapeutics Inc. for a treatment method for sepsis and related inflammatory conditions. Sepsis is a serious health issue that can lead to death and affects a large number of people in the United States. The patent describes a method of delivering therapeutic drugs locally to the spleen to modulate neuro-immune activity and treat sepsis. The method involves inserting a drug delivery system into the body and advancing it to the spleen through blood vessels. The drug delivery system can be used to stimulate or inhibit nerve activity and alter the release of cytokines to regulate the immune response and maintain immune homeostasis. Various drug delivery techniques are described, including catheter-based delivery and transvascular delivery. The patent also mentions other device-based treatments for sepsis that are currently in development. [Extracted from the article]

The New Mexico Lions Sight Conservation Foundation, Inc., also known as the New Mexico Lions Eye Bank, has received a warning letter from the United States Food and Drug Administration (FDA) for significant deviations from regulations regarding human cells, tissues, and cellular and tissue-based products (HCT/Ps). The FDA found that the foundation failed to determine as ineligible two donors of ocular HCT/Ps who had clinical evidence of sepsis. The foundation's procedures for determining donor eligibility also did not comply with FDA requirements. The FDA has requested a written response outlining the steps the foundation will take to correct the violations. [Extracted from the article]

Researchers from Baebies Inc. have submitted a patent application for a culture monitoring system and methods to detect sepsis at its earliest stages. The proposed system aims to provide rapid diagnostic procedures to complement or replace current culture approaches. It includes an incubation chamber, a temperature control device, a fluid-handling cartridge, and one or more processors to control temperature, fluid movement, and assay results. The system can be used to identify bacterial species and perform antimicrobial susceptibility testing. The patent application also describes methods for conducting assays using the system. [Extracted from the article]

A patent has been issued for a non-invasive intravascular volume index monitor developed by Masimo Corporation. The monitor aims to assist in the diagnosis and treatment of heart failure, sepsis, and edema by providing accurate measurements of fluid levels in the body. The system uses a non-invasive sensor to generate an intensity signal based on light interaction with a tissue site, allowing for the determination of an intravascular volume index level. This information can help healthcare providers make informed decisions about fluid administration and improve patient outcomes. [Extracted from the article]

A patent has been issued to Cormedix Inc. for methods and pharmaceutical compositions for treating Candida auris in blood. Candida auris is a species of fungus that causes candidiasis in humans, particularly in patients with weakened immune systems. The fungus is often acquired in hospitals and has attracted attention due to its multidrug resistance. The patent describes the use of taurolidine, a compound that can neutralize C. auris pathogens, in a pharmaceutical composition for treating blood-borne infections. The invention involves incorporating taurolidine into degradable nanoparticles for effective treatment. [Extracted from the article]

A new study conducted by researchers from the Henry M. Jackson Foundation for the Advancement of Military Medicine Inc. has identified different subtypes of sepsis based on gene expression in the host. The study analyzed the response to sepsis in participants from West Africa, Southeast Asia, and North America, and identified four sepsis subtypes with varying mortality rates. The findings provide insights into the molecular endotypes of sepsis and suggest potential immunotherapeutic interventions and biomarkers for predicting outcomes. The study highlights the need for precision medicine approaches to address the heterogeneity of sepsis and improve therapeutic interventions. [Extracted from the article]

A patent has been issued to B.R.A.H.M.s GmbH for a method of determining abnormal platelet levels in a patient. The method involves measuring the level of proADM or its fragments in a bodily fluid sample from a patient in an intensive care unit (ICU). If the level of proADM is above a certain threshold, the patient is kept in the ICU and additional or modified treatments for low platelet levels, thrombocytopenia, or disseminated intravascular coagulation (DIC) are initiated. The invention aims to provide diagnostic and prognostic tools for identifying patients at high risk of adverse events associated with abnormal platelet levels. [Extracted from the article]

A patent has been issued to Beckman Coulter Inc. for a method of determining sepsis in the presence of blast flagging. Sepsis is a life-threatening condition caused by infection, and diagnosing it can be challenging. The method involves evaluating the monocyte distribution width (MDW) measured from a blood sample, with elevated MDW values indicating sepsis or the onset of sepsis. The presence of blasts, which are immature cells, can interfere with the evaluation of sepsis using MDW, but this method accounts for blast proliferation and provides a more accurate assessment. [Extracted from the article]

A patent application has been submitted for a method and kit to identify bacteria that cause sepsis, a serious condition resulting from bacterial infections. The method involves using a PCR method with specific primers and probes to detect the presence or absence of certain genes in the bacteria. The kit includes reagents for PCR and can be used with blood samples. This method and kit aim to quickly identify the causative bacteria of sepsis and start appropriate treatment. This technology has potential applications in diagnosing and treating sepsis. [Extracted from the article]

Tianjin Chase Sun Pharmaceutical Co. Ltd. has been granted a patent for a multi-component injection based on traditional Chinese medicine principles. The injection is designed to treat sepsis, a life-threatening infection. It contains active ingredients that have been shown to have pharmacological effects such as fighting bacterial endotoxins, reducing inflammation, and improving immune dysfunction. Clinical studies have demonstrated that the injection can lower mortality rates, shorten hospital stays, and improve outcomes for sepsis patients. The patent provides details on the specific ingredients and the method of preparation, which involves extracting and filtering natural compounds and plant extracts. The resulting injection has a pH value of 5.5-7.0 and can be administered through various injection methods. The patent is owned by Tianjin Chase Sun Pharmaceutical Co. Ltd. and was filed in April 2021. [Extracted from the article]

A recent study compared the efficacy of different antioxidant therapies in treating sepsis and septic shock in the intensive care unit (ICU). The study analyzed 56 trials involving 9,366 patients and found that melatonin with propolis was effective in improving Sequential Organ Failure Assessment (SOFA) scores. High-dose vitamin C, vitamin C with vitamin B1, and melatonin were identified as potential therapies for organ dysfunction. Melatonin and high-dose vitamin C were also found to be the most effective in reducing 28-day mortality rates. However, the results for 28-day mortality rates were not statistically significant. The study provides new insights into antioxidant therapy treatments for sepsis and septic shock in the ICU. [Extracted from the article]

Citius Pharmaceuticals has announced positive results from a Phase 3 clinical trial of its antibiotic lock solution, Mino-Lok. The trial showed a statistically significant improvement in the time to failure event in patients receiving Mino-Lok compared to those receiving a clinician-directed anti-infective lock solution. The data suggest that Mino-Lok could potentially become a new standard of care for patients with central line-associated infections or catheter-related bloodstream infections, offering a non-invasive treatment option compared to catheter removal and replacement. The company plans to engage with the US Food and Drug Administration to determine the next steps for Mino-Lok. [Extracted from the article]

Synedgen Inc. has been issued a patent for methods of treating or preventing damage resulting from radiation, trauma, or shock. The patent describes methods of identifying and treating subjects exposed to these stresses by administering a compound that reduces sepsis or mortality. The compound is described by a specific formula and is effective in reducing the severity of sepsis or symptoms, delaying its onset, or reducing the likelihood of mortality. The patent also includes methods for reducing permeability of the gastrointestinal tract in subjects exposed to radiation, trauma, or shock. [Extracted from the article]

Beckman Coulter Diagnostics and MeMed have expanded their partnership to advance host immune response diagnostics. Beckman Coulter is now an authorized distributor of the MeMed BV assay, a rapid immunoassay test that can distinguish between bacterial and viral infections. This new distribution agreement complements their joint effort to develop a MeMed BV-based test for Beckman Coulter's family of Access Immunoassay Analyzers. The MeMed BV assay has been shown to support or alter physician decision-making in 87% of cases, and it has a negative predictive value of over 99% to rule out bacterial infection. This partnership aims to improve infection management and provide clinicians with a more efficient diagnostic workflow. [Extracted from the article]

A patent has been issued to Kurin Inc. for a blood sample optimization system and blood contaminant sequestration device and method. The invention aims to reduce blood culture contamination, lysing of cells, and vein collapse during blood sample collection. The system includes a blood sequestration device with an inlet, outlet, sequestration chamber, and sampling channel. It allows for the passive withdrawal of blood using the patient's own blood pressure, reducing the risk of vein collapse. The device also includes a vent with an air permeable blood barrier to prevent contamination. This invention has the potential to improve patient outcomes and reduce healthcare costs associated with blood culture contamination. [Extracted from the article]